Clinical Trial

Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More

Study acronym: FOxTROT2France
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Colon cancer (CC) is the 5th most common cancer worldwide. Standard care for locally advanced disease is surgical resection followed by 3-6 months of adjuvant chemotherapy (AC) with oxaliplatin and 5-fluorouracil (OxFp). Almost all of these patients undergo surgery, but many do not receive AC due to frailty (following surgery). This particularly affects patients over 70, who represent the majority of patients diagnosed with CC. FOxTROT 2, a trial to test the role of NAC in older patients.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-02-27; most recent amendment 2025-03-25.
Status change: Not Yet Recruiting → Recruiting 2024-06-10
Trial Details
NCT Number NCT06293625
Lead Sponsor Centre Hospitalier Universitaire Dijon
Conditions Colon Cancer
Enrollment 150 participants
Start Date 2024-06-07
Primary Completion 2032-06 (estimated)
Study Completion 2032-06 (estimated)
Updated on ClinicalTrials.gov 2025-03-30